Calliditas Therapeutics: Reiterating our Valuation
Redeye reiterates its positive stance on Calliditas following the termination of the proposed global offering. While the situation caused uncertainty among investors, we also recognize that nothing fundamental in the case has changed. We reiterate our Base case of SEK 250 per share.